Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- SPHK-2 SK-2 SPK-2 TNF? IL6 Lipopolysaccharide U-937 10009237
- Product Overview:
Sphingosine kinase 2 (SPHK2) is an ATP-dependent lipid kinase that is encoded by the SPHK2 gene in humans.{53257} It is composed of an N-terminal domain that contains an ATP binding site and a C-terminal domain that mediates substrate binding and specificity. SPHK2 is localized to the mitochondria, nucleus, and endoplasmic reticulum and is expressed in a wide variety of tissues, including the liver and kidney.{14581} Upon cellular stimulation with EGF, phorbol 12-myristate 13-acetate (PMA; Item No. 10008014), or Fc?RI, SPHK2 is activated and catalyzes phosphorylation of sphingosine to sphingosine-1-phosphate (S1P).{53257,53258} SPHK2 has roles in many physiological and pathological processes, including cancer, inflammation, and neurodegenerative diseases.{53257,14482,53261,53259,53260} Pharmacological inhibition of SPHK2 decreases intracellular S1P levels in U937 cells, but genetic deletion or pharmacological inhibition of SPHK2 in mice increases blood S1P levels, an effect that has not been fully characterized but may be related to reduced S1P clearance in the blood in the absence of SPHK2 activity.{38413} Overexpression of SPHK2 increases intracellular calcium levels and induces apoptosis in NIH3T3 cancer cells and reduces LPS-induced increases in TNF-? and IL-6 levels in isolated human peripheral blood mononuclear cell-derived macrophages in vitro.{14482,53261} SPHK2 activity is increased in postmortem frontal cortex from patients with Alzheimer’s disease.{53260} Cayman’s Sphingosine Kinase 2 (human, recombinant) protein can be used for Western blot, ELISA, and enzymatic assays.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.